Survival and Its Predictors Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma in Ethiopia: A 6-Year Follow-Up Study
PURPOSETo analyze survival and its predictors among patients with hepatocellular carcinoma (HCC) receiving transarterial chemoembolization (TACE) in Ethiopia.MATERIALS AND METHODSWe conducted a retrospective cohort study among patients who received TACE for HCC at MCM Hospital from December 1, 2016,...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Society of Clinical Oncology
2025-01-01
|
| Series: | JCO Global Oncology |
| Online Access: | https://ascopubs.org/doi/10.1200/GO-24-00468 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832577565483597824 |
|---|---|
| author | Abigia Ashenafi Soliyana Demelash Efrata Melaku Haymanot Abe Meron Yitna Fisseha Tekle Jiksa Dabessa Biniam Araya Yared Nigussie Wondmagegn Demsiss Ashenafi Zelalem Song Jung Kim Nebiyu Dereje |
| author_facet | Abigia Ashenafi Soliyana Demelash Efrata Melaku Haymanot Abe Meron Yitna Fisseha Tekle Jiksa Dabessa Biniam Araya Yared Nigussie Wondmagegn Demsiss Ashenafi Zelalem Song Jung Kim Nebiyu Dereje |
| author_sort | Abigia Ashenafi |
| collection | DOAJ |
| description | PURPOSETo analyze survival and its predictors among patients with hepatocellular carcinoma (HCC) receiving transarterial chemoembolization (TACE) in Ethiopia.MATERIALS AND METHODSWe conducted a retrospective cohort study among patients who received TACE for HCC at MCM Hospital from December 1, 2016, to December 31, 2022. Data were extracted from patients' medical records, and vital status was ascertained from the patients' charts or by phone call to the next of kin. We used Kaplan-Meier estimator to determine survival functions and log-rank test to compare the survival functions in different groups. Predictors of survival were identified using a multivariable Cox proportional hazards regression model as expressed by adjusted hazard ratio (aHR).RESULTSOf the total 257 patients included in the study, 68.9% were male, with a mean age of 56.5 (±14.06) years, and 86% were diagnosed at the advanced stage of the cancer (Barcelona Clinic Liver Cancer-C). The median overall survival was 12.7 months (95% CI, 10.57 to 14.85), and the overall survival rate at 1 year, 2 years, 3 years, 4 years, 5 years, and 6 years was found to be 58.0% (95% CI, 51.8% to 63.8%), 24.1% (95% CI, 19.1% to 29.6%), 8.2% (95% CI, 5.1% to 11.7%), 7.0% (95% CI, 3.9% to 10.1%), 1.6% (95% CI, 0.4% to 3.1%), and 1.2% (95% CI, 0.1% to 2.7%), respectively. The probability of death was significantly increased by alpha-fetoprotein level <400 ng/mL (aHR, 5.72 [95% CI, 1.52 to 21.51]), albumin level (aHR, 5.03 [95% CI, 1.41 to 18.01]), and bilobar distribution (aHR, 5.67 [95% CI, 1.40 to 23.04]).CONCLUSIONThe findings of the study underscore the need for the expansion of preventive measures and treatment facilities to address the overwhelming burden of HCC in Ethiopia. |
| format | Article |
| id | doaj-art-e663124bd44c456b842e56c619ae181e |
| institution | Kabale University |
| issn | 2687-8941 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | American Society of Clinical Oncology |
| record_format | Article |
| series | JCO Global Oncology |
| spelling | doaj-art-e663124bd44c456b842e56c619ae181e2025-01-30T20:59:05ZengAmerican Society of Clinical OncologyJCO Global Oncology2687-89412025-01-011110.1200/GO-24-00468Survival and Its Predictors Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma in Ethiopia: A 6-Year Follow-Up StudyAbigia Ashenafi0Soliyana Demelash1Efrata Melaku2Haymanot Abe3Meron Yitna4Fisseha Tekle5Jiksa Dabessa6Biniam Araya7Yared Nigussie8Wondmagegn Demsiss9Ashenafi Zelalem10Song Jung Kim11Nebiyu Dereje12Department of Medicine, Myungsung Medical College, Addis Ababa, EthiopiaDepartment of Medicine, Myungsung Medical College, Addis Ababa, EthiopiaDepartment of Medicine, Myungsung Medical College, Addis Ababa, EthiopiaDepartment of Medicine, Myungsung Medical College, Addis Ababa, EthiopiaDepartment of Medicine, Myungsung Medical College, Addis Ababa, EthiopiaMCM Comprehensive Specialized Hospital, Addis Ababa, EthiopiaMCM Comprehensive Specialized Hospital, Addis Ababa, EthiopiaMCM Comprehensive Specialized Hospital, Addis Ababa, EthiopiaMCM Comprehensive Specialized Hospital, Addis Ababa, EthiopiaDepartment of Public Health, Myungsung Medical College, Addis Ababa, EthiopiaDepartment of Public Health, Myungsung Medical College, Addis Ababa, EthiopiaDepartment of Medicine, Myungsung Medical College, Addis Ababa, EthiopiaDepartment of Public Health, Myungsung Medical College, Addis Ababa, EthiopiaPURPOSETo analyze survival and its predictors among patients with hepatocellular carcinoma (HCC) receiving transarterial chemoembolization (TACE) in Ethiopia.MATERIALS AND METHODSWe conducted a retrospective cohort study among patients who received TACE for HCC at MCM Hospital from December 1, 2016, to December 31, 2022. Data were extracted from patients' medical records, and vital status was ascertained from the patients' charts or by phone call to the next of kin. We used Kaplan-Meier estimator to determine survival functions and log-rank test to compare the survival functions in different groups. Predictors of survival were identified using a multivariable Cox proportional hazards regression model as expressed by adjusted hazard ratio (aHR).RESULTSOf the total 257 patients included in the study, 68.9% were male, with a mean age of 56.5 (±14.06) years, and 86% were diagnosed at the advanced stage of the cancer (Barcelona Clinic Liver Cancer-C). The median overall survival was 12.7 months (95% CI, 10.57 to 14.85), and the overall survival rate at 1 year, 2 years, 3 years, 4 years, 5 years, and 6 years was found to be 58.0% (95% CI, 51.8% to 63.8%), 24.1% (95% CI, 19.1% to 29.6%), 8.2% (95% CI, 5.1% to 11.7%), 7.0% (95% CI, 3.9% to 10.1%), 1.6% (95% CI, 0.4% to 3.1%), and 1.2% (95% CI, 0.1% to 2.7%), respectively. The probability of death was significantly increased by alpha-fetoprotein level <400 ng/mL (aHR, 5.72 [95% CI, 1.52 to 21.51]), albumin level (aHR, 5.03 [95% CI, 1.41 to 18.01]), and bilobar distribution (aHR, 5.67 [95% CI, 1.40 to 23.04]).CONCLUSIONThe findings of the study underscore the need for the expansion of preventive measures and treatment facilities to address the overwhelming burden of HCC in Ethiopia.https://ascopubs.org/doi/10.1200/GO-24-00468 |
| spellingShingle | Abigia Ashenafi Soliyana Demelash Efrata Melaku Haymanot Abe Meron Yitna Fisseha Tekle Jiksa Dabessa Biniam Araya Yared Nigussie Wondmagegn Demsiss Ashenafi Zelalem Song Jung Kim Nebiyu Dereje Survival and Its Predictors Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma in Ethiopia: A 6-Year Follow-Up Study JCO Global Oncology |
| title | Survival and Its Predictors Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma in Ethiopia: A 6-Year Follow-Up Study |
| title_full | Survival and Its Predictors Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma in Ethiopia: A 6-Year Follow-Up Study |
| title_fullStr | Survival and Its Predictors Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma in Ethiopia: A 6-Year Follow-Up Study |
| title_full_unstemmed | Survival and Its Predictors Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma in Ethiopia: A 6-Year Follow-Up Study |
| title_short | Survival and Its Predictors Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma in Ethiopia: A 6-Year Follow-Up Study |
| title_sort | survival and its predictors among patients receiving transarterial chemoembolization for hepatocellular carcinoma in ethiopia a 6 year follow up study |
| url | https://ascopubs.org/doi/10.1200/GO-24-00468 |
| work_keys_str_mv | AT abigiaashenafi survivalanditspredictorsamongpatientsreceivingtransarterialchemoembolizationforhepatocellularcarcinomainethiopiaa6yearfollowupstudy AT soliyanademelash survivalanditspredictorsamongpatientsreceivingtransarterialchemoembolizationforhepatocellularcarcinomainethiopiaa6yearfollowupstudy AT efratamelaku survivalanditspredictorsamongpatientsreceivingtransarterialchemoembolizationforhepatocellularcarcinomainethiopiaa6yearfollowupstudy AT haymanotabe survivalanditspredictorsamongpatientsreceivingtransarterialchemoembolizationforhepatocellularcarcinomainethiopiaa6yearfollowupstudy AT meronyitna survivalanditspredictorsamongpatientsreceivingtransarterialchemoembolizationforhepatocellularcarcinomainethiopiaa6yearfollowupstudy AT fissehatekle survivalanditspredictorsamongpatientsreceivingtransarterialchemoembolizationforhepatocellularcarcinomainethiopiaa6yearfollowupstudy AT jiksadabessa survivalanditspredictorsamongpatientsreceivingtransarterialchemoembolizationforhepatocellularcarcinomainethiopiaa6yearfollowupstudy AT biniamaraya survivalanditspredictorsamongpatientsreceivingtransarterialchemoembolizationforhepatocellularcarcinomainethiopiaa6yearfollowupstudy AT yarednigussie survivalanditspredictorsamongpatientsreceivingtransarterialchemoembolizationforhepatocellularcarcinomainethiopiaa6yearfollowupstudy AT wondmagegndemsiss survivalanditspredictorsamongpatientsreceivingtransarterialchemoembolizationforhepatocellularcarcinomainethiopiaa6yearfollowupstudy AT ashenafizelalem survivalanditspredictorsamongpatientsreceivingtransarterialchemoembolizationforhepatocellularcarcinomainethiopiaa6yearfollowupstudy AT songjungkim survivalanditspredictorsamongpatientsreceivingtransarterialchemoembolizationforhepatocellularcarcinomainethiopiaa6yearfollowupstudy AT nebiyudereje survivalanditspredictorsamongpatientsreceivingtransarterialchemoembolizationforhepatocellularcarcinomainethiopiaa6yearfollowupstudy |